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Abstract
Objective
In a representative population of women followed over 34 years, we investigated the pro-
spective association between fasting serum insulin and dementia, taking into account the
incidence of diabetes mellitus.
Methods
Fasting values for serum insulin and blood glucose were obtained in 1,212 nondiabetic women
38 to 60 years of age at the 1968 baseline. Risk of dementia was assessed by Cox proportional
hazard regression with adjustment for insulin, glucose, and other covariates and, in a second
model, after censoring for incident cases of diabetes mellitus. Incident diabetes mellitus was
considered as a third endpoint for comparison with dementia.
Results
Over 34 years, we observed 142 incident cases of dementia. The low tertile of insulin displayed
excess risk for dementia (hazard ratio [HR] 2.34, 95% conﬁdence interval [CI] 1.52–3.58)
compared to the medium tertile, but the high tertile of insulin did not (HR 1.28, 95% CI
0.81–2.03). These associations were also seen for dementia without diabetes comorbidity. In
contrast, high but not low insulin predicted incident diabetes mellitus (115 cases) (HR 1.70,
95% CI 1.08–2.68 and HR 0.76, 95% CI 0.43–1.37, respectively).
Conclusion
A previous study reported a U-shaped association between fasting insulin and dementia in a 5-
year follow-up of elderly men. Our results conﬁrmed a nonlinear association in a female
population, with high risk at low insulin values that was not attributable to preclinical dementia
or impaired insulin secretion. This condition suggests a new pathway to dementia, which diﬀers
from the metabolic pathway involving diabetes mellitus.
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Epidemiologic studies have observed associations between fast-
ing insulin levels and risk of dementia, almost exclusively fo-
cusing on the high end of the insulin distribution and considering
mainly the role of type 2 diabetes mellitus (T2DM).1–4 How-
ever, one study of elderly community-dwelling men followed up
over 5 years showed that fasting insulin levels were related to risk
of dementia in a U-shaped functional form, with elevated hazard
ratios (HRs) at both ends of the insulin spectrum.5 Sensitivity
analyses examined reverse causation, i.e., preclinical dementia
causing low insulin values, but the association with low insulin
levels remained. Produced in the pancreatic β cells, insulin enters
the brain by a receptor-mediated, saturable transport mecha-
nism, and brain insulin levels are proportional to peripheral levels
under physiologic conditions.6–9 A U-shaped association be-
tween serum insulin and dementia is therefore plausible on the
basis of clinical evidence regarding hyperinsulinemia10 and in-
sulin deﬁciency in the brain.7,11,12 It has been pointed out that
the latter could also be a consequence of previous peripheral
hyperinsulinemia and T2DM.7,8,13
The purpose of this study was to investigate the association
between fasting insulin and dementia in a female population
followed over 34 years. The long observation period reduces
the risk of reverse causation, i.e. the levels of fasting insulin
being inﬂuenced by preclinical disease. Importantly, we take
into account information on prevalent and incident diabetes
diagnoses that were previously shown to predict dementia in
these women.14 Using the same cohort and follow-up in-
formation, we aim to investigate whether both high and low
fasting serum insulin levels in midlife predict dementia and
how this association is related to diabetes comorbidity.
Methods
Study population
In 1968, a representative sample of 1,622 women 38, 46, 50, 54,
or 60 years of age and living inGothenburg, Sweden, were invited
to the Prospective Population Study ofWomen inGothenburg.15
A total of 1,462 women (90%) accepted the invitation and
attended comprehensive physical and psychiatric examinations,
at which they completed questionnaires about education, life-
style, and medical history. Follow-up examinations were carried
out in 1974, 1980, 1992, and 2000,with participation rates among
those still alive decreasing from 91% in 1968 to 71% in 2000.16,17
Standard protocol approvals, registrations,
and patient consents
Participants provided informed oral consent in 1968, 1974,
and 1980 and written consent in 1992 and later. Since 1980,
all examinations have been approved by the Regional Ethics
Review Board in Gothenburg in accordance with the Decla-
ration of Helsinki.
Endpoint definitions
The diagnosis of dementia was based on the combined in-
formation from psychiatric examinations and close informant
interviews according to the DSM-III-R and on diagnostic data
from the hospital discharge register and medical records from
inpatient and outpatient departments and general practi-
tioners’ oﬃces in Gothenburg for all women, including those
lost to follow-up.18 Dementia subtypes were determined by
geriatric psychiatrists and categorized as probable or possible
Alzheimer disease (AD), vascular dementia (VD), or other
dementia.19 Dementia diagnoses until December 31, 2002,
were included in this report.
Diabetes mellitus was assessed at baseline and at each follow-
up examination, and its incidence was recorded until the end
of 2002.20 A woman was deﬁned as having diabetes mellitus if
the diagnosis was made by a physician, if she was on antidi-
abetic medication, or if her fasting blood glucose concentra-
tion was ≥7.0 mmol/L, in accordance with the current World
Health Organization deﬁnition of diabetes mellitus.21 The
information from examinations was checked for consistency
with information from the Swedish Patient Register. Survivors
who did not attend a certain follow-up examination were
asked to complete a short postal questionnaire that included
a question concerning diabetes status. Except for 2 cases of
type 1 diabetes mellitus at baseline, all incident cases were
T2DM.
Baseline variables
At baseline (1968), venous blood samples were taken in all
participants after an overnight fast, and fasting glucose was
determined with a ferric cyanide reduction method adapted
for autoanalyzer by Technicon.22 Fasting insulin was mea-
sured in serum samples from 1968 stored at −20°C for 45
years and validated by comparison with values that had been
analyzed at baseline in a subsample of participants using
a double antibody method.23 The analysis was performed in
the Clinical Chemistry Laboratory at Sahlgrenska University
Hospital, Mo¨lndal, Sweden, with Elecsys kits on a Cobas 6000
analyzer (Roche Diagnostics, Basel, Switzerland) by board-
certiﬁed laboratory technicians blinded to clinical data. Be-
cause absolute values were generally low, indicating an
underestimation of the original values, we performed a non-
parametric analysis based on tertiles that focused on the
nonlinear relationship with risk of dementia. Secondary
analyses were based on calibrated insulin values that were
Glossary
AD = Alzheimer disease; BMI = body mass index; CI = conﬁdence interval; DSM-III-R = Diagnostic and Statistical Manual of
Mental Disorders, 3rd edition, revised;HOMA = homeostatic model assessment;HR = hazard ratio; LTPA = leisure time physical
activity; T2DM = type 2 diabetes mellitus; VD = vascular dementia.
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obtained from comparison of mean values in frozen relative to
fresh samples, yielding a calibration factor of 1.88.23 These
calibrated insulin values were used to derive approximate cut
points characterizing the nonlinear association with risk of
dementia and to estimate insulin sensitivity and β-cell func-
tion according to the homeostatic model assessment
(HOMA) based on the updated computer model.24,25
Body mass index (BMI) was calculated from weight and
height measured by standardized protocols.15 Obesity was
deﬁned as BMI ≥30 kg/m2. Hypertension was deﬁned as
systolic or diastolic blood pressure ≥140 or 90 mm Hg, re-
spectively, in the sitting position after 5 minutes of rest or use
of antihypertensive treatment. Total cholesterol, triglycerides,
and leptin were measured in baseline blood samples as de-
scribed previously.23,26 Hypertriglyceridemia was deﬁned as
triglyceride values ≥1.7 mmol/L.27 Higher education was
deﬁned as more than basic education. Parental history of di-
abetes mellitus was based on self-reported information col-
lected at all examinations (at least 1 parent with diabetes vs
none). Self-rated leisure time physical activity (LTPA) was
assessed in 3 categories distinguishing low (sedentary life-
style), moderate, and high LTPA.28 Smoking was assessed as
current or previous smoking during the last 10 years vs never
smoking or giving up smoking >10 years ago. Consumption of
beer, wine, and spirits was dichotomized into current vs never
or former use of each beverage. In 502 women participating in
the fourth follow-up examination in 2000,29 APOE genotype
was determined and parametrized in terms of the number of
e4 alleles per participant.
Analytic sample
Prevalent cases of diabetes mellitus at baseline (n = 14) were
excluded from the analysis because treatment may have af-
fected the levels of insulin and glucose. Because no more
serum samples from 1968 were available for 230 participants,
the analytic sample was based on 1,218 women free of di-
abetes mellitus with values for insulin and glucose, which was
reduced to 1,212 observations as a result of missing values for
education or alcohol consumption. Among these, 142 women
developed dementia before 2003, with a mean follow-up time
to diagnosis of 25 years (SD = 6.1 years). The subtypes AD (n
= 92) and VD (n = 66) were not mutually exclusive; 31
women had both diagnoses. The remaining 15 cases were
other subtypes of dementia.19 Nineteen of 142 cases of de-
mentia also had diabetes mellitus, and 4 of these were di-
agnosed within 9 years after dementia diagnosis. To separately
investigate dementia diagnoses that were not mediated by
diabetes mellitus, we considered dementia without any di-
agnosis of diabetes mellitus as an additional endpoint (n =
123), treating dementia with diabetes comorbidity as a com-
peting event. The competing events included diabetes melli-
tus after the dementia diagnosis because the mean time
diﬀerence of 3.8 years (range 1–9 years) was short compared
to the latency period of dementia and because diabetes mel-
litus may be underdiagnosed in individuals with dementia.
Because HOMA insulin sensitivity and β-cell function were
deﬁned only for glucose in (3.0–25.0) mmol/L and insulin in
(2.88–57.6) mIU/L, the number of observations was reduced
to 1,169 in regression models including these variables.
Statistical methods
Fasting insulin was parameterized in terms of tertiles, which
allowed us to examine the nonlinear association with de-
mentia with consideration of the limited number of cases.
Because of its correlation with insulin (r2 = 0.30, p < 0.001),
fasting glucose was included as a potential confounder and
parameterized in terms of tertiles as well. Cut points based on
the analytic sample were given by 10.3 and 14.8 mIU/L (in-
sulin) and 3.8 and 4.3 mmol/L (glucose). Risk of dementia
was assessed by Cox proportional hazard regression mutually
adjusted for tertiles of insulin and glucose, and for important
covariates. Because age is the strongest risk factor for de-
mentia, age at diagnosis or censoring was chosen as the rel-
evant time scale, with left truncation at age at the baseline
examination. To examine the risk for dementia without di-
abetes comorbidity, observations with both dementia and
diabetes diagnosis were censored at the age at the earlier
diagnosis. To examine the association with dementia sub-
types, proportional hazard regression on tertiles of insulin and
glucose was performed with stepwise forward selection of
covariates (p for inclusion = 0.1, p for staying in the model =
0.05). Proportional hazard regression was also applied to in-
vestigate the eﬀect of insulin and glucose on the risk for di-
abetes mellitus. Covariates included education, BMI, BMI
squared, categories of LTPA, alcohol consumption, smoking
status, and heredity for diabetes mellitus (for diabetes end-
points only). In sensitivity analyses, we further adjusted for
potential confounders such as hypertension, total cholesterol,
hypertriglyceridemia, leptin, and the number of APOE e4
alleles. Leptin was log-transformed before analysis to reduce
skewness. To further illustrate the nonlinear association with
risk of dementia, we performed proportional hazard re-
gression for insulin parameterized in terms of restricted cubic
splines30 with 4 knots, automatically placed at 6.6, 10.4, 14.4,
and 25.3 mIU/L. The median value of 12.3 mIU/L was
chosen as the reference, and observations with the 1% lowest
and 1% highest insulin values were excluded from the analysis.
Post hoc analyses on quintiles of fasting insulin were per-
formed to show the independence of associations on speciﬁc
cut points (data available from Dryad, ﬁgure, doi.org/10.
5061/dryad.21v1r72). To examine interactions between in-
sulin and age, we also deﬁned regression models with time
from baseline to event or censoring as the underlying time
scale and included age and age squared as predictor variables.
The proportional hazards assumption was assessed with cu-
mulative sums of martingale residuals (ASSESS option in the
regression routine PHREG in SAS, SAS Institute Inc, Cary,
NC), and variables were included only if there was no in-
dication of a violation of the proportional hazard assumption
(p > 0.05). Multicollinearity between predictors was assessed
by separate linear models for survival until dementia di-
agnosis. Results presented here are based on regression
models that did not show evidence for multicollinearity
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(variance inﬂation factors <2). All analyses were performed
with SAS version 9.4 and MATLAB (R2016b; MathWorks,
Inc, Natick, MA). Results with values of p < 0.05 were con-
sidered statistically signiﬁcant (2-sided tests).
Data availability
Anonymized data might be shared by request.
Results
Baseline characteristics of participants are shown in table 1.
Fasting insulin showed a larger variability than fasting
glucose because the latter was restricted by an upper limit
of 7.0 mmol/L in this sample of women without diabetes
mellitus at baseline. Because of their association with di-
abetes mellitus, we also calculated estimates for insulin
sensitivity and β-cell function to examine whether the state
of low fasting insulin was a consequence of reduced
production due to impaired β-cell function and preclinical
diabetes mellitus. Insulin sensitivity and β-cell function
were estimated from fasting values of insulin and glucose
with HOMA, with insulin sensitivity being the inverse of
HOMA insulin resistance.25 Because of restrictions re-
garding the values of fasting insulin and glucose, the
number of observations for HOMA variables was reduced
to 1,169. Mean BMI was in the range of normal weight, and
the prevalence of obesity was 8%. Most of the participants
had only basic education, which was the norm for women
born during the ﬁrst decades of the 20th century. More
than 80% of women reported regular physical activity, and
almost half of the sample reported ever smoking.
Table 2 shows the association between tertiles of insulin
mutually adjusted for tertiles of glucose with 3 diﬀerent
endpoints, namely incident dementia, dementia censored
for diabetes mellitus, and diabetes mellitus (panel A). Being
in the low tertile of fasting insulin more than doubled the
risk of dementia compared to being in the medium tertile,
HR = 2.34 (1.52–3.58), while the high tertile was not sig-
niﬁcantly associated with higher risk of dementia. These
associations were also seen with respect to dementia out-
comes without a lifetime diagnosis of diabetes mellitus
(column 2). In contrast, high but not low insulin was asso-
ciated with a higher risk of diabetes (column 3). Compared
to the medium tertile, the high tertile of glucose predicted
dementia and was marginally associated with higher risk of
diabetes mellitus. Panel B shows that lower values of HOMA
insulin sensitivity predicted diabetes mellitus in a dose-
dependent way, while HOMA β-cell function was not as-
sociated with diabetes mellitus. Regarding dementia end-
points, reduced risk was seen for low and medium tertiles of
HOMA insulin sensitivity compared to the high tertile.
Lower values for HOMA β-cell function were associated
with a higher risk of dementia.
The nonlinear association between fasting insulin and risk of
dementia is further illustrated with the use of proportional
hazard regression with restricted cubic splines (ﬁgure). We
derived a value of 10.3 mIU/L for the approximate inﬂection
point, below which the risk of dementia is increased. Post hoc
analyses based on quintiles showed increased risk of dementia
for women in the ﬁfth quintile (fasting insulin ≥17.8 mIU/L)
compared to the fourth quintile (HR 2.48; 95% conﬁdence
interval [CI] 1.31–4.71; data available fromDryad, ﬁgure, doi.
org/10.5061/dryad.21v1r72).
To investigate the association of fasting insulin and glucose
with dementia subtypes while accounting for the smaller
number of events, proportional hazard regression on ter-
tiles of insulin and glucose was performed with stepwise
selection of covariates from variables describing education,
lifestyle, and BMI. For VD, low insulin predicted dementia
independently of diabetes comorbidity (table 3). Addi-
tional predictors of VD were BMI and ever smoking, but
BMI was no longer a predictor of VD censored for diabetes
Table 1 Characteristics of the analytic sample at baseline
(n = 1,212, population study of women in
Gothenburg, 1968–2003)
Mean (SD)
Age, y 47.5 (6.3)
Insulin, mIU/L 13.9 (7.1)
Glucose, mmol/L 4.1 (0.7)
HOMA insulin sensitivity, %a 72 (32)
HOMA β-cell function, %a 207 (73)
BMI, kg/m2 24.1 (3.7)
n (%)
More than basic education 375 (31)
Parental history of diabetes mellitus 149 (12)
Obesity 91 (8)
LTPA
Low 214 (18)
Moderate 855 (70)
High 143 (12)
Ever smoking 542 (45)
Current use of alcohol
Beer 819 (68)
Wine 610 (50)
Spirits 322 (27)
Abbreviations: BMI = body mass index; HOMA = homeostatic model as-
sessment; LTPA = leisure time physical activity.
a For fasting values of glucose in (3.0–25.0) mmol/L and calibrated insulin in
(2.88–57.6) mIU/L (n = 1,169); note that values >100% are common.24,25
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mellitus. AD was predicted by low insulin, and this asso-
ciation was strengthened after censoring for diabetes
comorbidity. Other covariates did not predict AD. When
participants with <20 years of follow-up were excluded in
sensitivity analyses, the associations between variables de-
scribing insulin and glucose metabolism and dementia
outcomes were strengthened (data available from Dryad,
table 1, doi.org/10.5061/dryad.21v1r72).
Table 4 gives the characteristics of covariates and the
number of incident cases of diabetes mellitus, dementia,
and mortality by fasting insulin tertile. Compared to
women in the medium tertile of insulin, those in the low
insulin tertile had lower values of glucose and HOMA β-cell
function and higher values of HOMA insulin sensitivity.
They also had lower BMI, blood pressure, and heart rate;
had lower values of triglycerides and leptin; and were less
likely to be hypertensive. They were more likely to have
higher education, to be physically active, to be a smoker, or
to consume alcohol. APOE e4 allele frequency was higher in
the low insulin tertile compared to higher tertiles. There
was no diﬀerence in diabetes incidence but a higher in-
cidence of dementia in the low compared to the medium
tertile. In contrast, being in the high insulin tertile was
associated with high values of cardiovascular risk factors
and with excess risk of diabetes mellitus. Total mortality
showed a U-shaped risk curve with respect to insulin. A
corresponding analysis of tertiles of fasting glucose showed
fewer contrasts with regard to covariates and endpoints
(data available from Dryad, table 2, doi.org/10.5061/
dryad.21v1r72). The age-adjusted analysis demonstrated
excess risk for diabetes mellitus in the high glucose tertile,
although this is highly dependent on insulin and BMI, as
shown in the mutually adjusted model (table 2; data
available from Dryad, table 3).
Further adjustment of the model for dementia for variables
associated with insulin hardly changed the estimates for
insulin and glucose given in table 2. Among these potential
confounders, only hypertriglyceridemia (HR 1.96, 95% CI
Table 2 HRs (CIs) for total dementia, dementia censored for diabetesmellitus, and diabetesmellitus,mutually adjusted for
tertiles of insulin and glucose (panel A), and for tertiles of HOMA insulin sensitivity and β-cell function (panel B)
Dementia Dementia without T2DM Diabetes mellitus
A Events/total, n 142/1,212 123/1,212 115/1212
Tertiles of fasting insulina
Low 2.34c (1.52–3.58) 2.32c (1.48–3.63) 0.76 (0.43–1.37)
Medium (referent) 1 1 1
High 1.28 (0.81–2.03) 1.21 (0.73–2.00) 1.70d (1.08–2.68)
Tertiles of fasting glucosea
Low 0.77 (0.50–1.21) 0.81 (0.51–1.30) 1.05 (0.63–1.75)
Medium (referent) 1 1 1
High 1.56d (1.05–2.32) 1.58d (1.03–2.42) 1.42 (0.90–2.24)
B Events/total, n 139/1,169 120/1,169 111/1,169
Tertiles of HOMA insulin sensitivitya,b
Low 0.88 (0.55–1.39) 0.74 (0.45–1.23) 3.28c (1.76–6.11)
Medium 0.57e (0.37–0.88) 0.56d (0.36–0.88) 1.74 (0.94–3.23)
High (referent) 1 1 1
Tertiles of HOMA β-cell functiona,b
Low 2.17e (1.32–3.58) 1.89d (1.10–3.24) 1.29 (0.79–2.13)
Medium 2.01e (1.23–3.27) 1.81d (1.06–3.08) 1.04 (0.66–1.65)
High (referent) 1 1 1
Abbreviations: CI = confidence interval; HOMA = homeostatic model assessment; HR = confidence interval; T2DM = type 2 diabetes mellitus.
Adjusted for age, education, BMI, smoking, alcohol consumption, physical activity, and heredity of diabetes mellitus (for diabetes endpoints only).
a Tertiles for insulin: 10.3, 14.8 mIU/L; glucose: 3.8, 4.3 mmol/L; HOMA insulin sensitivity: 56%, 80%, HOMA β-cell function: 170%, 224%.
b For fasting values of glucose in (3.0–25.0) mmol/L and calibrated insulin in (2.88–57.6) mIU/L (n = 1,169).
c p < 0.001.
d p < 0.05.
e p < 0.01.
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1.23–3.12) and higher cholesterol (HR 1.14, 95% CI
1.04–1.25) predicted dementia (data available from Dryad,
table 4, doi.org/10.5061/dryad.21v1r72). Adjusting for
APOE genotype restricted the sample to those participants
who survived until 2000 (n = 502). To reduce survival bias,
we excluded the oldest women (60 years old at baseline, n =
4) ensuring that there was no age diﬀerence by insulin
tertile. In this subsample, low insulin predicted dementia
(HR 3.01, 95% CI 1.56–5.84) compared to the medium
insulin tertile independently of higher APOE e4 allele fre-
quency (HR 2.18, 95% CI 1.29–3.67) per allele (data
available from Dryad, table 4, right column).
Discussion
In this population-based study of middle-aged women free of
diabetes mellitus at baseline, the 34-year risk of dementia was
more than doubled in women with initially low fasting serum
insulin compared to women with medium insulin values. The
association was independent of fasting glucose, BMI, educa-
tion, and lifestyle factors and was strengthened when follow-
up was restricted to ≥20 years, refuting the hypothesis that
low insulin was a consequence of weight loss often seen in the
prodromal phase of dementia. The association with low
fasting insulin was also seen when dementia without diabetes
comorbidity was the outcome of interest, considering de-
mentia with diabetes mellitus as a competing event. Regarding
incident diabetes mellitus, the largest risk was observed for
high vs medium values of fasting insulin, and no risk at all was
seen for low insulin. Low insulin values at the baseline of the
34-year follow-up thus cannot be interpreted as a sign of
reduced insulin secretion due to preclinical T2DM. This
Figure HR for dementia as a function of fasting insulin us-
ing restricted cubic splines
Cubic spline regressionmodel with 4 knots at 6.6, 10.4, 14.5, and 25.3mIU/L,
excluding the 1% lowest and 1% highest values of fasting insulin. Reference
is set at 12.3mIU/L (median). Themodel is adjusted for age, education, body
mass index, smoking, alcohol consumption, physical activity, and tertiles of
fasting glucose. The p value for test of nonlinearity is 0.0002. Artwork was
performed with MATLAB (R2016b; MathWorks, Inc, Natick, MA). CI = confi-
dence interval; HR = hazard ratio.
Table 3 HRs (95% CIs) for dementia subtypes including and censored for T2DM as a function of fasting insulin and
glucose, from age-parameterized models with stepwise selection of covariates
VDa VDa without T2DM ADa ADa without T2DM
Events/total, n 66/1,212 59/1,212 92/1,212 79/1,212
Tertiles of fasting insulina
Low 2.33b (1.25–4.36) 2.06c (1.09–3.89) 1.88c (1.13–3.14) 2.13b (1.23–3.67)
Medium (referent) 1 1 1 1
High 1.17 (0.60–2.30) 1.23 (0.60–2.52) 1.28 (0.75–2.19) 1.17 (0.64–2.14)
Tertiles of fasting glucosea
Low 0.68 (0.37–1.27) 0.68 (0.36–1.29) 0.85 (0.50–1.46) 0.85 (0.48–1.52)
Medium (referent) 1 1 1 1
High 1.04 (0.58–1.85) 0.97 (0.52–1.81) 1.44 (0.88–2.36) 1.53 (0.90–2.61)
Selected covariates
BMI 1.09c (1.02–1.17)
Ever smoking 1.77c (1.07–2.94) 1.74c (1.03–2.94)
Abbreviations: AD = Alzheimer disease; BMI = body mass index; CI = confidence interval; HR = confidence interval; T2DM = type 2 diabetes mellitus; VD =
vascular dementia.
a Note that the diagnoses AD and VD are partially overlapping.
b p < 0.01.
c p < 0.05.
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Table 4 Covariates of fasting insulin (unadjustedmean values and frequencies with p values from regressionmodels on
age and insulin tertiles)
Baseline variables
Serum insulin, mIU/L
Tertile 1 (n = 405) Tertile 2 (referent) (n = 403) Tertile 3 (n = 404)
8.2 (3.0–10.3)a 12.4 (10.3–14.8)a 21.2 (14.8–85.4)a
Mean (SD) Mean (SD) Mean (SD)
Age, y 47.2 (5.9) 47.3 (6.0) 48.0 (6.9)
Glucose, mmol/L 3.92 (0.59)f 4.07 (0.58) 4.34 (0.75)f
HOMA insulin sensitivity, % 106 (30)f 67 (8) 42 (10)f
HOMA β-cell function, % 162 (43)f 203 (54) 255 (82)f
BMI, kg/m2 22.7 (2.9)f 23.8 (3.1) 25.8 (4.2)f
SBP, mm Hg 128 (20)g 132 (20) 141 (24)f
DBP, mm Hg 81 (10)g 83 (10) 87 (11)f
Heart rate, bpm 76 (11)f 80 (12) 86 (13)f
Triglycerides, mmol/L 1.06 (0.38)g 1.14 (0.41) 1.43 (0.74)f
Total cholesterol, mmol/L 6.70 (1.03) 6.79 (1.05) 7.04 (1.47)g
Leptin, μg/L 8.7 (5.1)f 11.3 (6.0) 14.7 (9.1)f
n (%) n (%) n (%)
More than basic education 157 (39)g 120 (30) 98 (24)
Parental history of diabetes mellitus 49 (12) 53 (13) 47 (12)
Hypertension 109 (27)g 150 (37) 219 (54)f
Hypertriglyceridemia 24 (6) 31 (8) 99 (25)f
LTPAb
Low 73 (18) 65 (16) 76 (19)
Moderate (referent) 265 (65) 297 (74) 293 (73)
High 67 (17)g 41 (10) 35 (9)
Ever smoking 217 (54)f 161 (40) 164 (41)
Current use of alcohol
Beer 296 (73) 280 (70) 243 (60)g
Wine 238 (59)h 203 (50) 169 (42)h
Spirits 138 (34)g 101 (25) 83 (21)
APOE «4 allele frequencyc,d 66 (18.6)h 46 (12.6) 29 (10.1)
Incident disease/mortality before 2003
Diabetes mellitus 19 (5) 31 (8) 65 (16)f
Dementia 64 (16)g 36 (9) 42 (10)
VDe 30 (7)h 16 (4) 20 (5)
ADe 38 (9) 25 (6) 29 (7)
Mortality 165 (41)f 120 (30) 185 (46)f
Abbreviations: AD = Alzheimer disease; BMI = bodymass index; DBP = diastolic blood pressure; HOMA = homeostatic model assessment; LTPA = leisure time
physical activity; SBP = systolic blood pressure; VD = vascular dementia.
a Mean value (range).
b From multinomial logistic regression of low or high vs moderate LTPA on insulin tertiles and age.
c From ordinal logistic regression of the number of APOE e4 alleles on insulin tertiles in the subset of women participating in 2000 (first tertile n = 177, second
tertile n = 182, third tertile n = 143).
d The percentage of e4 alleles was calculated as number of e4 alleles/(2 × number of participants).
e Note that the diagnoses AD and VD are partially overlapping.
f p < 0.001.
g p < 0.01.
h p < 0.05 from regression on age and insulin tertiles (referent = second tertile).
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conclusion is supported by the observation that low HOMA
insulin sensitivity predicted incident diabetes mellitus, but low
HOMA β-cell function did not. These ﬁndings suggest that
the state of low fasting insulin characterizes an alternative
pathway to dementia that is diﬀerent from the one via
hyperinsulinemia and T2DM.
While risk of dementia due to hyperinsulinemia has been
shown previously,1,3 the present study is the ﬁrst to replicate
the observation of an adverse association between low fasting
insulin values and dementia, which was described in a cohort
of elderly men followed up over 5 years.5 Our results gener-
alize this ﬁnding to women while enhancing the evidence for
a causal association because the 34-year follow-up, with
a minimum of 20 years in sensitivity analyses, decreased the
probability of reverse causation for dementia. Third, the ob-
servation that low insulin predicted dementia without di-
abetes comorbidity, and not diabetes mellitus, makes it
possible to identify hypoinsulinemia as a risk factor for de-
mentia that is fundamentally diﬀerent from hyperinsulinemia
or diabetes mellitus. This was in contrast to the previously
mentioned study in which about one-third of all men had
diabetes mellitus at baseline and incident diabetes mellitus
was not accounted for.5 In addition, the women in the present
study were recruited in the late 1960s when the prevalence of
obesity was still low. It is possible that the proportion of
subjects with low insulin was relatively large compared to
modern cohorts, which may have made it more likely to ob-
serve the association with dementia in the present sample.
The phenotype associated with low insulin was characterized
by low body weight, low blood pressure and heart rate, and
low values of glucose, triglycerides, and leptin. These associ-
ations were not explained by cigarette smoking or high
physical activity, lifestyle variables that were also associated
with low insulin in both this study and previous studies.31,32
Twenty years ago, Bonora et al.33 described a U-shaped risk
curve for fasting insulin and coronary heart disease in a cross-
sectional study. They found similar correlates with low insulin
as demonstrated here and postulated that this condition, de-
spite high insulin sensitivity, presented a state of insuﬃcient
cell insulinization, promoting the development of athero-
sclerosis. If low serum insulin is a marker for low insulin in the
brain, it may, through its role as a mitogenic growth factor,
cause impaired neuronal functioning, cell death, and
dementia.3,7 This interpretation is supported by recent in vivo
clinical results showing that low levels of fasting blood insulin
were associated with increased β-amyloid deposition and
neurodegeneration in nondiabetic, cognitively normal older
adults.34 Consistent with these ﬁndings, the association be-
tween low insulin and dementia described here was particu-
larly strong for VD and for AD without diabetes comorbidity,
i.e., when the alternative pathway through diabetes mellitus
was censored. Although insulin concentrations in the CSF are
generally well below serum levels, the ratio varies between 1%
and 10%, depending on weight status and other factors that
regulate the transport across the blood-brain barrier8 and
inﬂuence brain insulin levels in addition to absolute levels of
circulating insulin. However, sensitivity analyses showed that
none of the covariates that correlated with serum insulin
explained the reported associations with dementia endpoints,
underlining the fundamental importance of insulin for the
etiology of dementia.
Comparedwith the risk due to low fasting insulin, the excess risk
due to high insulin was less pronounced in this study, whichmay
be due to the secular changes in BMI as mentioned above and
the fact that women with T2DM at baseline were excluded from
the sample. Compared to the other 2 insulin tertiles, the high
insulin tertile had a low prevalence of the APOE e4 allele and
a high incidence of diabetes mellitus, which is consistent with
observations that diabetesmellitus as a risk factor for dementia is
more often observed in noncarriers of the APOE e4 allele.4,35,36
The main strengths of this study are the assessment of risk
factors in midlife, the long follow-up that reduces the risk of
reverse causation due to preexisting dementia, and the high
quality of endpoint data regarding both diabetes mellitus and
dementia. A limitation of the study is that insulin was mea-
sured in serum samples that had been stored at −20°C for
45 years. Although validated in a subsample with baseline
measurements in fresh samples, values were generally
underestimated.23 Nonparametric regression models were
used to reduce the inﬂuence of misclassiﬁcation, but precise
cut points for theU-shaped association with dementia should be
derived from studies using fasting insulin obtained in fresh
samples. In view of the pulsatile mode of insulin secretion even
in the fasting state,37 the lack of more than 1 insulin measure-
ment is acknowledged as further limitation. Moreover, the small
number of endpoints available in the 34 years of follow-up limits
our power to study subtypes of dementia (AD, VD, dementia
with and without diabetes comorbidity) and interactions be-
tween, for example, insulin and glucose tertiles. Finally, we note
that the APOE genotype was known only in participants who
survived until 2000, which may have biased the associations
between fasting insulin, genotype, and dementia.
This study provides epidemiologic evidence for a new path-
way to dementia that is characterized by low fasting serum
insulin and diﬀers from the metabolic pathway via hyper-
insulinemia or diabetes mellitus. The identiﬁcation of the tails
of the U-shaped risk curve for insulin and dementia with
distinct mechanisms was possible because of the long follow-
up and by comparing the associations of insulin with diﬀerent
dementia endpoints and diabetes mellitus. The distinction
between alternative pathways may explain inconsistent epi-
demiologic ﬁndings regarding risk factors of dementia and its
subtypes, as well as open new avenues for prevention.
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